Benitec Biopharma announces positive interim Phase 1B/2A results for high and low dose BB-301

BNTC•2026-10-28

Benitec Biopharma announced positive interim Phase 1B/2A results for high and low dose BB-301. No serious adverse events have been reported in patients to date.

1. Interim trial results

Benitec Biopharma announced positive interim Phase 1B/2A results for high and low dose BB-301. The company said no serious adverse events have been reported in patients to date.

Benitec Biopharma announces positive interim Phase 1B/2A results for high and low dose BB-301

1. Interim trial results

Related News

Phillips 66 posts record quarterly profit on refining strength

Tarsus Pharmaceuticals appoints Neera Clase as chief commercial officer

Evogene targets acute graft-versus-host disease in AI-driven drug discovery program

UK budget: Healey sets out response to 'global economic storms'

S&P 500, Nasdaq set for higher open as SK Hynix lifts chips; Fed in focus